UBS Maintains Neutral on Teladoc Health, Raises Price Target to $9

Benzinga · 2d ago
UBS analyst Kevin Caliendo maintains Teladoc Health (NYSE:TDOC) with a Neutral and raises the price target from $6.5 to $9.